FEATURED PRESS RELEASE
Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards.
Nadia K. Waheed, MD, MPH appointed Chief Medical Officer and Jane Hughes, PhD appointed Chief Scientific Officer.
GYROSCOPE THERAPEUTICS SECURES £50.4 MILLION IN SERIES B FINANCING TO CONTINUE CLINICAL DEVELOPMENT OF GENE THERAPIES AND SURGICAL DELIVERY SYSTEMS FOR RETINAL DISEASES
Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, today announced the successful completion of a £50.4 million Series B financing.
Merger brings together sub-retinal surgical delivery technology with Gyroscope’s clinical stage pipeline and gene therapy manufacturing platform.
Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases, has commenced dosing in a Phase I/II clinical trial in dry age-related macular degeneration (AMD).
Gyroscope Therapeutics led consortium secures INNOVATE UK funding to develop a suspension platform for cost effective manufacture of novel AAV gene therapies
Gyroscope Therapeutics and Freeline Therapeutics are partnering with two research organisations, NHSBT’s Clinical Biotechnology Centre (CBC) and the Centre for Process Innovation (CPI), to develop and design a manufacturing platform to produce novel (adeno-associated virus) AAV gene therapies.
Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases such as age related macular degeneration (AMD), is pleased to announce the appointment of Dr Soraya Bekkali as Chief Executive Officer and Director of its Board.